HDM2017 plus standard care for advanced colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This early-stage trial tests a new drug called HDM2017 combined with standard colorectal cancer treatment. It's designed for patients with advanced colorectal cancer that cannot be surgically removed, to see if this combination can help slow or shrink the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with advanced colorectal cancer (locally advanced or spread to other parts of the body) confirmed by biopsy
- At least 18 years old and in good enough health to handle treatment (ECOG performance status 0–1)
- Have at least one tumor that can be measured on imaging scans
- Able to provide a sample of tumor tissue from previous procedures
- Adequate organ function (heart, liver, kidney, blood counts) based on lab tests
- Expected to live at least 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (fruquintinib, chidamide, and sintilimab) for people with a specific type of metastatic colorectal cancer that has not responded to at least two prior treatments. It aims to see if this combination is safe and effective.
This trial tests a new drug called HDM2017 in people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and how it affects tumors.
This trial tests a combination of a targeted therapy pill (TKI) and an immunotherapy (PD-1 inhibitor) for people with advanced colorectal cancer that has stopped responding to standard treatments. It uses a blood test to tailor the treatment, aiming to be more effective with fewer side effects.
This trial tests a combination of two targeted drugs (fruquintinib and a drug that targets EGFR) as a third-line treatment for people with a specific type of colorectal cancer that has not responded to previous therapies. It may offer a new option for patients whose tumors are 'wild-type' for certain genes.
This trial tests a new drug, HDM2012, in people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective, especially for gastric and colorectal cancers.
This trial tests a new combination of two drugs (DSP107 and atezolizumab) compared to another drug (fruquintinib) for people with advanced colorectal cancer that hasn't responded to standard treatments. The goal is to find a more effective treatment option.
Hear when a new Colorectal Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.